Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Gets USFDA Nod for Generic Hypertension Drug
Details : Inderal-Generic (propranolol) is a β-adrenoceptors antagonist. It is now approved for the treatment of hypertension, angina pectoris, migraine, hypertrophic subaortic stenosis.
Brand Name : Inderal-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 14, 2024
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada
Details : Propranolol hydrochloride tablet is a synthetic beta-adrenergic receptor blocking agent, which is indicated for the treatment of the management of hypertension.
Brand Name : Inderal-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 29, 2023
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pfizer Recalls Inderal- LA (Propranolol Hydrochloride) Capsules Due to a Nitrosamine Impurity
Details : Pfizer Canada is recalling all lots of Inderal-LA (propranolol hydrochloride) extended release capsules, in 60 mg, 80 mg, 120 mg and 160 mg strengths, due to the presence of a nitrosamine impurity (N-nitroso-propranolol) above the acceptable level.
Brand Name : Inderal-LA
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2022
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : ATNAHS PHARMA UK LIMITED
Deal Size : $390.0 million
Deal Type : Divestment
AstraZeneca divests rights to established hypertension medicines
Details : AstraZeneca is seeking $350 million from Atnahs Pharma for global trade rights to a series of five hypertension drugs off-patent: Inderal, Tenormin, Tenoretic, Zestril and Zestoretic.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $350.0 million
January 27, 2020
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : ATNAHS PHARMA UK LIMITED
Deal Size : $390.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?